Inflammatory Bowel Disease Diagnostistic

Antibody differentiates between ulcerative colitis and Crohn’s disease

  • Serum-based dignostic biomarker
  • Simple, ELISA-based test
  • Differentiates between ulcerative colitis versus Crohn’s disease

 
Licensing Manager: Catherine Murari-Kanti, Ph.D.
catherine.murari@unmc.edu or 402-559-3265
 

Description

Antibody differentiates between ulcerative colitis and Crohn’s disease

Inventors at UNMC have developed a noninvasive blood test that can differentiate inflammatory bowel disease patients with high confidence, predicting disease severity and setting up a path for therapy response.
 
Inflammatory Bowel Disease is a group of chronic disorders where ulcerative colitis (UC) and Crohn’s disease (CD) are the principal manifestations. The cause remains uncertain and proper diagnosis requires a multitude of expensive, invasive, uncomfortable and potentially life-threatening procedures. A clear and accurate diagnosis is frustratingly difficult because UC and CD are so similar.
 
UNMC researcher found that malondialdehyde, a product of lipid peroxidation, reacts with acetaldehyde and forms a unique malondialdehyde-acetaldeyde adduct, or MAA for short. MAA promotes inflammatory responses and triggers cytokine secretions. These adducts have a pathogenic role to play in the initiation and progression of chronic inflammatory diseases such as rheumatoid arthritis and cardiovascular disease, to name a few.
 
The novel blood test uses the presence of MAA as a way ti differentiate between UC and CD.
 
To learn more about this diagnostic marker or to discuss licensing and collaboration opportunities, please contact Catherine Murari-Kanti, Ph.D. at catherine.murari@unmc.edu or 402-559-3265.